A Phase 3 interventional study of Tenecteplase and Endovascular Treatment in Medium Vessel Occlusion Stroke (MeVO) and Acute Ischemic Stroke, sponsored by The First Affiliated Hospital of University of Science and Technology of China. Not yet recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.
Sponsored by The First Affiliated Hospital of University of Science and Technology of China · Phase 3, Interventional, and Treatment
Among 11 studies in Ischemic Stroke by The First Affiliated Hospital of University of Science and Technology of China — 7 open to participants now, 7 under way, 2 of them phase 3. Ischemic Stroke · The First Affiliated Hospital of University of Science and Technology of China.
Among the 11 studies in Ischemic Stroke by The First Affiliated Hospital of University of Science and Technology of China, this one has the largest planned enrollment, is one of 2 that started in 2026, is one of 3 in phase 3, and was the 11th registered.
2,612 studies on the registry are indexed under Ischemic Stroke; 971 are open to participants now.
Browse Ischemic Stroke studies →7 of the 11 studies in Ischemic Stroke by The First Affiliated Hospital of University of Science and Technology of China are open now, in 1 country. Recruiting first, the newest first:
The First Affiliated Hospital of University of Science and Technology of China · Sites in China
Ages 18–85
The First Affiliated Hospital of University of Science and Technology of China · Sites in China
Ages 18–100
The First Affiliated Hospital of University of Science and Technology of China · Sites in China
Ages 18+
The First Affiliated Hospital of University of Science and Technology of China · Sites in China
Ages 18+
The First Affiliated Hospital of University of Science and Technology of China · Sites in China
Ages 18+
By country, each count listing its studies:
Of the 655 Ischemic Stroke studies recruiting now, 394 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 26 take children under 18; 41 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 1 · Phase 3 4
First in 2022; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,395 is above the median of 120 across 1,776 interventional studies indexed under Ischemic Stroke.
Median enrollment 560 across the 11 interventional studies. Of the 4 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
The First Affiliated Hospital of University of Science and Technology of China is the lead sponsor of 21 studies on the registry; 13 are open to participants now.
1 of the studies in Ischemic Stroke by The First Affiliated Hospital of University of Science and Technology of China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07094763The First Affiliated Hospital of University of Science and Technology of ChinaEfficacy and Safety of Tenecteplase Intravenous Thrombolysis in Acute Posterior Circulation Ischemic Stroke Within 4.5-24 Hours After Onset | 2027-10-30 |
Add it to your calendar (.ics) → With an account.
Among the 11 studies in Ischemic Stroke by The First Affiliated Hospital of University of Science and Technology of China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This trial compares intravenous thrombolysis (IVT) alone, endovascular treatment (EVT) alone, and bridging therapy (IVT followed immediately by EVT) in patients with acute ischemic stroke due to medium vessel occlusion (MeVO) and a baseline National Institutes of Health Stroke Scale (NIHSS) score ≥6. The hypotheses are that EVT alone and bridging therapy each increase the proportion of patients with functional independence at 90 days compared with IVT alone. This is a multicenter, prospective, randomized, open-label trial with blinded outcome assessment. Patients will be randomized 1:1:1 within 24 hours of symptom onset or last known well. The primary outcome is functional independence, defined as a modified Rankin Scale (mRS) score of 0 to 2 at 90 days.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
The other ingredients in a medicine besides the active drug, such as fillers, colours or preservatives.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colours or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive intravenous tenecteplase 0.25 mg/kg (maximum 25 mg) as a single bolus. Endovascular treatment is not performed.
Drug: Tenecteplase
Participants receive endovascular treatment without intravenous thrombolysis.
Procedure: Endovascular Treatment
Participants receive intravenous tenecteplase 0.25 mg/kg (maximum 25 mg) as a single bolus, followed immediately by endovascular treatment.
Drug: Tenecteplase · Procedure: Endovascular Treatment
Intravenous tenecteplase 0.25 mg/kg (maximum 25 mg) is administered as a single bolus.
Also known as: rhTNK-tPA, recombinant human TNK tissue-type plasminogen activator, Mingfule
A credentialed neurointerventionalist selects stent-retriever thrombectomy, aspiration thrombectomy, or intra-arterial thrombolysis. Intra-arterial thrombolysis uses tenecteplase, alteplase, or urokinase. Thrombectomy uses approved low-profile aspiration catheters or stent retrievers, generally with no more than three passes in the target vessel. The procedure is stopped earlier if further manipulation is judged unsafe.
Functional Independence at 90 Days
Proportion of participants with a modified Rankin Scale (mRS) score of 0 to 2 at 90 days, assessed by a blinded rater. The mRS ranges from 0 (no symptoms) to 6 (death).
Time frame: 90 days after randomization (±14 days)
Symptomatic Intracranial Hemorrhage Within 36 Hours
Proportion of participants with symptomatic intracranial hemorrhage within 36 hours of randomization, classified as definite or probable according to the Heidelberg Bleeding Classification. This is the primary safety outcome.
Time frame: Within 36 hours after randomization
Shift in Modified Rankin Scale Score Distribution at 90 Days
Distribution of mRS scores at 90 days. The mRS ranges from 0 (no symptoms) to 6 (death).
Time frame: 90 days after randomization (±14 days)
Modified Rankin Scale Score of 0 to 1 at 90 Days
Proportion of participants with an mRS score of 0 to 1 at 90 days. The mRS ranges from 0 (no symptoms) to 6 (death).
Time frame: 90 days after randomization (±14 days)
Modified Rankin Scale Score of 0 to 3 at 90 Days
Proportion of participants with an mRS score of 0 to 3 at 90 days. The mRS ranges from 0 (no symptoms) to 6 (death).
Time frame: 90 days after randomization (±14 days)
Early Neurological Improvement at 24 Hours
Proportion of participants with an improvement in the National Institutes of Health Stroke Scale (NIHSS) score of ≥4 points from baseline or an NIHSS score of 0 to 1 at 24 hours. The NIHSS ranges from 0 to 42, with higher scores indicating more severe neurological deficits.
Time frame: 24 hours after treatment (±6 hours)
NIHSS Score at 24 Hours
The NIHSS ranges from 0 to 42, with higher scores indicating more severe neurological deficits.
Time frame: 24 hours after treatment (±6 hours)
Change From Baseline in NIHSS Score at 24 Hours
Change in NIHSS score from baseline to 24 hours, calculated as the 24-hour score minus the baseline score. The NIHSS ranges from 0 to 42, with higher scores indicating more severe neurological deficits.
Time frame: Baseline and 24 hours after treatment (±6 hours)
Barthel Index at 90 Days
Activities of daily living at 90 days assessed using the Barthel Index total score. Scores range from 0 to 100, with higher scores indicating greater independence.
Time frame: 90 days after randomization (±14 days)
EQ-5D-5L Utility Index at 90 Days
EQ-5D-5L utility index at 90 days, calculated with the Chinese value set (Luo et al., 2017). The index ranges from -0.391 to 1.000, with higher values indicating better health.
Time frame: 90 days after randomization (±14 days)
Successful Reperfusion
Proportion of participants with successful reperfusion, defined as an expanded Thrombolysis in Cerebral Infarction (eTICI) score ≥2b50 on final angiography. This outcome is assessed in the EVT-alone and bridging groups.
Time frame: At final angiography during the endovascular procedure
First-Pass Effect
Proportion of participants achieving eTICI 2c to 3 reperfusion after the first thrombectomy pass without rescue treatment. This outcome is assessed in the EVT-alone and bridging groups.
Time frame: During the endovascular procedure
Successful Reperfusion at Initial Angiography
Proportion of participants randomized to bridging IVT plus EVT with successful reperfusion (eTICI ≥2b50) at initial angiography.
Time frame: At initial angiography during the endovascular procedure
All-Cause Mortality at 90 Days
Proportion of participants who die from any cause within 90 days after randomization.
Time frame: Within 90 days after randomization
Target Artery Recanalization at 24 to 72 Hours
Proportion of participants with patency of the target artery on computed tomography angiography (CTA) or magnetic resonance angiography (MRA), defined as a modified Arterial Occlusive Lesion (mAOL) score of 2 or 3. The mAOL scale ranges from 0 (no recanalization) to 3 (complete recanalization). This outcome is assessed in all three groups.
Time frame: 24 to 72 hours after randomization
Any Intracranial Hemorrhage at 24 Hours
Proportion of participants with any new intracranial hemorrhage identified on follow-up computed tomography (CT) or magnetic resonance imaging (MRI) and classified according to the Heidelberg Bleeding Classification.
Time frame: 24 hours after treatment (±6 hours)
Procedure-Related Vascular Complications
Proportion of participants with at least one vascular complication related to an endovascular procedure, including vessel perforation or dissection, distal embolization or embolization into a new vascular territory, vasospasm, acute vessel occlusion, and vascular access-site hematoma, bleeding, or pseudoaneurysm. Events will be adjudicated by an independent clinical events committee.
Time frame: During the endovascular procedure and through the 90-day follow-up (±14 days)
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Dec 2026; primary completion for Apr 2029, 28 months later.
Of 143 non-industry phase 3 interventional studies under Ischemic Stroke, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 62. This study's planned 28 months is below that.
Counting every sponsor, half of 165 studies reached it within 30 months; a quarter within 19 and three quarters within 52.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
The First Affiliated Hospital of University of Science and Technology of China